Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Naloxone Mandate In Opioid Labels Divides US FDA Panel, Even As It Wants Patient Conversations

Executive Summary

Advisory committee members vote narrowly in favor of labeling opioids with a recommendation to co-prescribe naloxone, but more agree that the goal is to facilitate patient-provider dialogue about overdose risks.
Advertisement

Related Content

Recent And Upcoming FDA Advisory Committee Meetings
US FDA’s Most Unusual Advisory Committee
Naloxone Sponsor Steps In Pricing Hole Disputing FDA's Cost Estimates
Cost Concerns May Hinder Naloxone Co-Prescribing Ideas
Opioid Prescribing Guidelines Will Be More Template Than Commandment
Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap

Topics

Advertisement
UsernamePublicRestriction

Register

PS124452

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel